Biotech · Private company · Dallas, TX, US
Oculogenex
Track this companyFree. Adds Oculogenex to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards1
- Developing a gene therapy-based solution for early intervention in age related macular degeneration (AMD) to prevent disease progressionFiscal year 2026 · $1.1MNIH RePORTER 1R44EY038510-01 · fetched Nov 12, 2026